Bahrain Medical Bulletin, August 1990, Vol. 12, No. 2 S]
EDITORIAL
Download article here
_____________________________________________________________________________________
_____________________________________________________________________________________
_____________________________________________________________________________________
Malignant hyperpyrexia’ is a potentially fatal complication of general anaesthesia. In the
affected individuals Suxamethonium and/or Halothane and other drugs can trigger a sudden rise in
body temperature which unless rapidly corrected is followed by convulsion and death in 60% of
cases. The reaction does not seem to depend upon any particular anaesthetic agent nor on the type
of surgery being performed. It has often developed in previously healthy individuals undergoing
relatively minor surgical procedure. The tendency to develop this complication is inherited as an
autosomal dominant characteristic.
Soon after induction of anaesthesia the muscles go into massive spasm, the body temperature
quickly rises to a high level and the patient becomes acidotic. It is probably the cardiac effect of the
acidosis which often causes sudden death.
Malignant hyperpyrexia is accompanied by the following biochemical changes”: serum creatine
phosphokinase (CPK) reaches high level within three hours after induction of anaesthesia which is
explained by muscle injury and damage; high level of serum glutamic oxalacetic transaminase
(SGOT) and lactate dehydrogenase (LDH); high level of serum phosphate which results in a fall of
serum calcium; and high levels of serum potassium and serum aldolase.
Denborough et al’ studied the family and three close relatives of a patient who had survived
malignant hyperpyrexia. They were found to have a very high level of serum creatine
phosphokinase (CPK). Although the patient’s muscles seemed normal, two of the three relatives
had a mild but definite myopathy, affecting predominantly the lower muscles of the thigh. It seems
that malignant hyperpyrexia develops in individuals with a myopathy which is inherited as an
autosomal dominant,* and which may be sub clinical. Therefore, all patients with myopathy and
their relatives may be at risk of malignant hyperpyrexia (indeed this syndrome was described first in
a patient with myotonia congenita).
Fortunately, affected individuals can be detected by a serum CPK estimation, all blood
relatives of the patient who had malignant hyperpyrexia should be examined clinically and screened
for raised serum CPK levels. It was advised that all individuals having general anaesthesia be
screened by a serum CPK estimation because the myopathy causing malignant hyperpyrexia may
not be detected clinically, and a family history of this rare disorder is usually not given. Whenever
serum CPK level is elevated from some other causes, the body temperature should be monitored
during anaesthesia, so that hyperpyrexia can be corrected at an early stage.
Muscle contracture tests used to be the corner stone for diagnosing patients with malignant
hyperpyrexia, the test is not easy and it can be done only in few centres in the world, while serum
CPK can be estimated in most Medical Centres.
________________________________________________________________________________
* Clinical Geneticist . Oo
Genetic Unit
Salmaniya Medical Centre
State of Bahrain
Whenever faced with an unexpected attack, all anaesthetic agent should be discontinued at
once and Dantrolene administered by rapid IV push, starting with 1 mg/kg and continue until the
symptom begin to subside.”: ° It is also advised to reduce the temperatue by vasodilator drugs, cool
the patient, correct acidosis and any electrolyte disturbance (hyperkalaemia), and support the
circulation.
REFERENCES
1. Emery AEH, Rimoin DL. Malignant hyperpyrexia : principle and practise of medical genetics.
Edinburgh: Churchill Livingstone 1983;2:1396-7.
2. Denborough MA, Forster JFA, Hudson MC, Carter NG, Zapf PW. Biochemical changes in malignant
hyperpyrexia. Lancet 1970;1:1137-8.
3. Denborough MA, Ebeling P, King JO, Zapf PW. Myopathy and malignant hyperpyrexia. Lancet
1970;1:1138-40.
4. McKusik VA. Hyperthermia of anaesthesia, 14560, Mendelian inheritance in man. Sth ed. Baltimore:
John Hopkins University Press, 1978:218.
5. Laurence DR, Bennett PN. Clinical Pharmacology. Sth ed. Edinburgh: Churchill Livingstone,
1980:357-92.
6. Modification of drug response. [Pharmacogenetics]. In: Berkow R, Fletcher AJ, Bondy PK, et al., eds.
The Merck manual. 5 ed. Rahway, NJ: Merck Sharp & Dohme: 1987:2455.
